BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Stem Cell News » Press Releases » Page 2

Ciloa’s project among the 11 winners of the “Sanofi iTech Awards”

February 15, 2021 By Cade Hildreth (CEO) Leave a Comment

Ciloa itech awards
  • French biotech company Ciloa wins the 2020 “Sanofi iTech Awards”.
  • The winning project is based on the unique innovation developed by Ciloa, which uses its customized exosomes for therapeutic purposes.
  • The “Sanofi iTech Awards” program funds and supports projects related to the development of innovative technologies in Healthcare that may lead to a subsequent research collaboration between Sanofi and Ciloa.

[Read more…]

Filed Under: Exosomes, Press Releases

Nucleus Biologics Launches Artificial Intelligence Research (NB-AIR): The World’s First AI Platform for Media Configuration That Gives Control Back To The Scientists

February 9, 2021 By Cade Hildreth (CEO) Leave a Comment

NB Air by Nucleus Biologics

SAN DIEGO, Feb. 9, 2021 — Nucleus Biologics™, The Cell Performance Company™, today announced the availability of NB-AIR™, the world’s first Artificial Intelligence Research platform for optimizing cell culture formulations for cell and gene therapies.  Leveraging cutting-edge AI algorithms, the system empowers scientists to create optimized formulas based on meta-analysis of peer-reviewed articles.  AI guided formulations will allow scientists to improve the performance of their cell therapy and shorten the time to get these lifesaving therapies into patients faster. [Read more…]

Filed Under: Press Releases

U.S. FDA Grants Approval of Fourth CAR-T Cell Therapy (Breyanzi) to Juno Therapeutics

February 6, 2021 By Cade Hildreth (CEO) Leave a Comment

Juno Therapeutics Breyanzi

On February 5, 2021, the U.S. FDA granted approval of Breyanzi (lisocabtagene maraleucel) to Juno Therapeutics, a Bristol-Myers Squibb Company. Breyanzi is a chimeric antigen receptor (CAR) T cell therapy approved for the treatment of adults with relapsed or refractory large-B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. [Read more…]

Filed Under: CAR-T, Press Releases

Renowned University of Miami Researcher Dr. Giacomo Lanzoni to Speak Tonight, Courtesy of the AASCP

February 3, 2021 By Cade Hildreth (CEO) Leave a Comment

Dr. Giacomo Lanzoni
Dr. Giacomo Lanzoni to speak on a live webcast hosted tonight, Wednesday, February 3, 2021, courtesy of The American Academy of Stem Cell Physicians!

The American Academy of Stem Cell Physicians (AASCP) offers various events tailored for doctors and the research community. It is constantly keeping up with the latest developments in regenerative medicine, including diagnosis, treatments, and prevention of diseases. In an exciting webcast to be held tonight, Wednesday, February 3, 2021, the AASCP will feature renowned researcher, Dr. Giacomo Lanzoni. [Read more…]

Filed Under: Press Releases, Stem Cell News

Award winning celebrity doctor secures a year’s worth of Stem Cell expansions exclusively for his patients

February 1, 2021 By Cade Hildreth (CEO) Leave a Comment

Lifeplus Stem cells Aamer Khan
LifePlus Stem Cells secures an exciting new partnership with award winning celebrity doctor Aamer Khan. The London based doctor has had a special interest in Regenerative Medicine for more than 10 years and is excited to offer his patients the very latest in stem cell therapies. His patients will be able to choose from umbilical cord tissue-derived mesenchymal stromal cells (allogeneic) or their own, purified and expanded, adipose tissue-derived stem cells (autologous) for various medical treatments.

[Read more…]

Filed Under: Press Releases, Stem Cell News

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 46
  • Next Page »

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected
    Rated 0 out of 5
    $197
  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • BioInformant Audience Reach BioInformant's Audience with Your Press Announcement
    Rated 0 out of 5
    $397 $297

Featured Posts

CellSource

Pediatric Stem Cell Transplantation Expert and Industry Leader Dr. Joseph Rosenthal Joins Cell Source’s Scientific Advisory Board

Feature | Exosome Companies | Exosome Companies | Tiny Exosomes, Enormous Potential

List of Exosome Companies: Tiny Packages, Enormous Potential

Dr. John Sessions

The American Academy of Stem Cell Physicians Pays Tribute to Dr. John Sessions, “Everyone’s Teacher”

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.